For the quarter ended February 2024, Neogen NEOG reported revenue of $228.81 million, up 4.8% over the same period last year. EPS came in at $0.12, compared to $0.12 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $229.94 million, representing a surprise of -0.49%. The company delivered an EPS surprise of -14.29%, with the consensus EPS estimate being $0.14.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Neogen performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Food Safety: $157.75 million versus $163 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +4.1% change.
- Revenues- Animal Safety: $71.06 million versus the three-analyst average estimate of $66.92 million. The reported number represents a year-over-year change of +6.5%.
- Revenues- Food Safety- Culture Media & Other: $81.17 million versus $82.48 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +4.1% change.
- Revenues- Animal Safety- Life Sciences: $1.37 million versus the two-analyst average estimate of $1.55 million. The reported number represents a year-over-year change of -4.7%.
- Revenues- Animal Safety- Animal Care & Other: $10.07 million versus the two-analyst average estimate of $9.42 million.
- Revenues- Food Safety- Rodent Control, Insect Control & Disinfectants: $10.14 million versus $10.72 million estimated by two analysts on average.
- Revenues- Animal Safety- Rodent Control, Insect Control & Disinfectants: $23.06 million compared to the $22.07 million average estimate based on two analysts.
- Revenues- Food Safety- Bacterial & General Sanitation: $40.40 million compared to the $42.50 million average estimate based on two analysts. The reported number represents a change of +2.4% year over year.
- Revenues- Food Safety- Natural Toxins, Allergens & Drug Residues: $19.74 million versus $21.11 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +2.8% change.
- Revenues- Animal Safety- Veterinary Instruments & Disposables: $17.98 million compared to the $14.03 million average estimate based on two analysts. The reported number represents a change of +16.5% year over year.
Shares of Neogen have returned -11.2% over the past month versus the Zacks S&P 500 composite's +1.7% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.